Literature DB >> 12853157

Antibody to CD14 like CXCR4-specific antibody 12G5 could inhibit CXCR4-dependent chemotaxis and HIV Env-mediated cell fusion.

Hengwen Yang1, Canhui Lan, Yi Xiao, Ying-Hua Chen.   

Abstract

The expression of HIV-1 coreceptors (CXCR4 and CCR5) on monocyte surface can be regulated by the ligand of CD14 (LPS), which stimulate the susceptibility of the cells to HIV-1. To investigate whether it exists potential association between CD14 and HIV-1 coreceptor CXCR4, we tested the impact of CD14-specific monoclonal antibodies (mAbs) upon CXCR4-dependent responses, such as SDF-induced chemotaxis and HIV Env-mediated membrane fusion. The anti-CD14 mAb TUK4 like CXCR4-specific mAb 12G5 could block SDF-induced chemotaxis of U937 cells in a dose-dependent manner, while another CD14-specific mAb UCHM-1 did not show any activity. More interestingly, syncytium assay indicated that only the CD14-specific mAb TUK4 inhibited HIV Env-mediated CXCR4-dependent cell fusion between U937 cells and HIV-1(HXB2) Env transfected CHO cells distinctly, consistent with its activity against CXCR4-dependent chemotaxis. These results provided experimental evidence for existence of close association between CD14 and HIV coreceptor CXCR4 on human monocytic cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12853157     DOI: 10.1016/s0165-2478(03)00048-8

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  2 in total

1.  CXCR4 antibody treatment suppresses metastatic spread to the lung of intratibial human osteosarcoma xenografts in mice.

Authors:  Patrick Brennecke; Matthias J E Arlt; Carmen Campanile; Knut Husmann; Ana Gvozdenovic; Tiziana Apuzzo; Marcus Thelen; Walter Born; Bruno Fuchs
Journal:  Clin Exp Metastasis       Date:  2014-01-04       Impact factor: 5.150

2.  Microtiter plate-based antibody-competition assay to determine binding affinities and plasma/blood stability of CXCR4 ligands.

Authors:  Mirja Harms; Andrea Gilg; Ludger Ständker; Ambros J Beer; Benjamin Mayer; Volker Rasche; Christian W Gruber; Jan Münch
Journal:  Sci Rep       Date:  2020-09-29       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.